Cervical Cancer – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Cervical Cancer – Pipeline Review, H1 2020’, provides an overview of the Cervical Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cervical Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cervical Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Cervical Cancer

– The report reviews pipeline therapeutics for Cervical Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Cervical Cancer therapeutics and enlists all their major and minor projects

– The report assesses Cervical Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Cervical Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Cervical Cancer

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Cervical Cancer pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3SBio Inc

Aadi Bioscience Inc

AbbVie Inc

Abion Inc

Abivax SA

Admedus Ltd

Advaxis Inc

Advenchen Laboratories LLC

Adze Biotechnology Inc

Affimed GmbH

Agenus Inc

Akeso Inc

Almac Discovery Ltd

Alphamab Oncology

amcure GmbH

Andes Biotechnologies

Anew Oncology Inc

AntiCancer Inc

Apimeds Inc

Apollomics Inc

Apotex Inc

Asana BioSciences LLC

Ascenta Therapeutics Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Bayer AG

BeiGene Ltd

Beijing Neoantigen Biotechnology Co Ltd

Beijing Recreation Guards Biotechnology Co Ltd

BioAtla LLC

Biocad

BIOCND Inc

Biocon Ltd

BioIntegrator Ltd

Bioleaders Corp

Biomics Biotechnologies Co Ltd

BioNTech SE

Boehringer Ingelheim International GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Co

Celleron Therapeutics Ltd

Cellestia Biotech AG

Cellid Co Ltd

Centus Biotherapeutics Ltd

Changchun Bcht Biotechnology Co Ltd

Chineo Med Beijing Co Ltd

Chong Kun Dang Pharmaceutical Corp

Clovis Oncology Inc

Convert Pharmaceuticals SA

Corvus Pharmaceuticals Inc

Cotinga Pharmaceuticals Inc

Cue Biopharma Inc

Cytocom Inc

CytomX Therapeutics Inc

CZ BioMed Corp

Daewon Pharmaceutical Co Ltd

Daiichi Sankyo Co Ltd

DelMar Pharmaceuticals Inc

Disulfican Ltd

EirGenix Inc

Eisai Co Ltd

Eli Lilly and Co

Epygen Biotech Pvt Ltd

Ervaxx Ltd

Etna Biotech Srl

Etubics Corp

Eubiologics Co Ltd

Exelixis Inc

EyeGene Inc

F. Hoffmann-La Roche Ltd

Fate Therapeutics Inc

Five Prime Therapeutics Inc

Flow Pharma Inc

Fujifilm Holdings Corp

GamaMabs Pharma SA

Gene Techno Science Co Ltd

Genentech Inc

Genetic Immunity Inc

Genexine Inc

Genmab AS

Gilead Sciences Inc

GlaxoSmithKline Plc

GlycoNex Inc

Glycostem Therapeutics BV

GlyTR Therapeutics Inc

GO Therapeutics Inc

Gradalis Inc

Hamlet Pharma AB

Harbin Gloria Pharmaceuticals Co Ltd

Hefei Ruichengsheng Biotechnology Co Ltd

Hookipa Pharma Inc

Huabo Biopharm Co Ltd

ImCheck Therapeutics SAS

Immune Therapeutics Inc

Immunitor Inc

ImmunityBio Inc

Immunomedics Inc

IMV Inc

Incyte Corp

Innate Pharma SA

Innovene

Innovent Biologics Inc

InSight Biopharmaceuticals Ltd

Invectys SA

Iovance Biotherapeutics Inc

ISA Pharmaceuticals BV

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

Juno Therapeutics Inc

Karyopharm Therapeutics Inc

Komipharm International Co Ltd

Kymab Ltd

Medical Guidance Systems LLC

Merck & Co Inc

Merck KGaA

Mereo Biopharma Group Plc

MicroQuin Ltd

Midissia Therapeutics Inc

Molecular Partners AG

Mundipharma EDO GmbH

Mycenax Biotech Inc

NeoTX Therapeutics Ltd

Newish Technology Beijing Co Ltd

Novartis AG

Noyan Pajouhan Biopharma

Ocellaris Pharma Inc

Onconova Therapeutics Inc

OncoSec Medical Inc

Ono Pharmaceutical Co Ltd

Oxford Vacmedix UK Ltd

Pfizer Inc

Pharma Mar SA

PharmAbcine Inc

Phoenix Life Sciences International Ltd

PI Therapeutics Ltd

Plus Therapeutics Inc

Potenza Therapeutics Inc

Precigen Inc

Prestige BioPharma Pte Ltd

Puma Biotechnology Inc

RAPT Therapeutics Inc

Regeneron Pharmaceuticals Inc

Rexahn Pharmaceuticals Inc

Richter Gedeon Nyrt

Samyang Holdings Corp

Sanofi

Savoy Pharmaceuticals Inc

Seattle Genetics Inc

Selecta Biosciences Inc

Shanghai Bovax Biotechnology Co Ltd

Shanghai Henlius Biotech Inc

Shanghai Institute of Biological Products Co Ltd

Shanghai Zerun Biotechnology Co Ltd

Shantha Biotechnics Pvt Ltd

Shattuck Labs Inc

SK Bioscience

Sorrento Therapeutics Inc

Sotio AS

Spring Bank Pharmaceuticals Inc

SQZ Biotechnologies Co

Starpharma Holdings Ltd

Suzhou Stainwei Biotech Inc

Synermore Biologics Co Ltd

Takeda Pharmaceutical Co Ltd

TCRCure Biotech Co Ltd

Tessa Therapeutics Pte Ltd

Theralase Technologies Inc

Theravectys SA

THEVAX Genetics Vaccine USA Inc

Transgene SA

Turnstone Biologics Inc

Vaccibody AS

Vascular Biogenics Ltd

Vectorite Biomedical Inc

ViciniVax BV

Vir Biotechnology Inc

Virion Therapeutics LLC

Virometix AG

VLP The Vaccines Company SL

VM Discovery Inc

Wuhan Binhui Biotechnology Co Ltd

Xencor Inc

Xiamen Innovax Biotech Co Ltd

Zeria Pharmaceutical Co Ltd

Zhejiang Yangshengtang Biotech Co Ltd

Zymeworks Inc

Table of Contents

Table of Contents

Introduction

Cervical Cancer - Overview

Cervical Cancer - Therapeutics Development

Cervical Cancer - Therapeutics Assessment

Cervical Cancer - Companies Involved in Therapeutics Development

Cervical Cancer - Drug Profiles

Cervical Cancer - Dormant Projects

Cervical Cancer - Discontinued Products

Cervical Cancer - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Cervical Cancer, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Cervical Cancer – Pipeline by 3SBio Inc, H1 2020

Cervical Cancer – Pipeline by Aadi Bioscience Inc, H1 2020

Cervical Cancer – Pipeline by AbbVie Inc, H1 2020

Cervical Cancer – Pipeline by Abion Inc, H1 2020

Cervical Cancer – Dormant Projects, H1 2020

Cervical Cancer – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Cervical Cancer, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports